2025 Japan 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 Japan 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine (PPSV23) market in Japan include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline (GSK), and Sanofi Pasteur. Pfizer is notable for its Pneumococcal Conjugate Vaccine (PCV13, Prevenar 13), which was approved for adult use in Japan and holds a significant market share globally, dominating the conjugate vaccine segment. Merck & Co. produces Pneumovax 23, the key 23-valent polysaccharide vaccine approved in Japan’s routine immunization schedule in 2014 and widely used for adults aged 65 and older. GSK contributes mainly through its Synflorix vaccine, focusing on pediatric and adult immunization, while Sanofi is involved with pneumococcal vaccine research, including candidate vaccines such as PCV15 in clinical trials .
These companies play strategic roles in Japan’s pneumococcal vaccine market, which generated over USD 107 million in 2023 and is projected to grow robustly. Pfizer’s vaccines have expanded indications enabling immunization of elderly adults, critical given Japan’s aging population. Merck’s PPSV23 coverage in adults with chronic conditions remains low but is a focus for increased public health efforts. GSK and Sanofi are also establishing their presence amidst government support and emerging vaccine innovations. This competitive landscape reflects active R&D, government immunization policies, and partnerships shaping market growth in Japan’s pneumococcal vaccine segment .
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine (PPSV23) market in Japan include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline (GSK), and Sanofi Pasteur. Pfizer is notable for its Pneumococcal Conjugate Vaccine (PCV13, Prevenar 13), which was approved for adult use in Japan and holds a significant market share globally, dominating the conjugate vaccine segment. Merck & Co. produces Pneumovax 23, the key 23-valent polysaccharide vaccine approved in Japan’s routine immunization schedule in 2014 and widely used for adults aged 65 and older. GSK contributes mainly through its Synflorix vaccine, focusing on pediatric and adult immunization, while Sanofi is involved with pneumococcal vaccine research, including candidate vaccines such as PCV15 in clinical trials .
These companies play strategic roles in Japan’s pneumococcal vaccine market, which generated over USD 107 million in 2023 and is projected to grow robustly. Pfizer’s vaccines have expanded indications enabling immunization of elderly adults, critical given Japan’s aging population. Merck’s PPSV23 coverage in adults with chronic conditions remains low but is a focus for increased public health efforts. GSK and Sanofi are also establishing their presence amidst government support and emerging vaccine innovations. This competitive landscape reflects active R&D, government immunization policies, and partnerships shaping market growth in Japan’s pneumococcal vaccine segment .
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
